Innate Pharma (IPHYF) Non-Current Assets (2017 - 2025)

Innate Pharma's Non-Current Assets history spans 9 years, with the latest figure at $18.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 31.12% year-over-year to $18.6 million; the TTM value through Dec 2025 reached $18.6 million, down 31.12%, while the annual FY2025 figure was $18.6 million, 31.99% down from the prior year.
  • Non-Current Assets reached $18.6 million in Q4 2025 per IPHYF's latest filing, down from $27.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $147.8 million in Q4 2021 to a low of $18.6 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $56.7 million, with a median of $29.2 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: fell 7.44% in 2021, then tumbled 58.97% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $147.8 million in 2021, then crashed by 58.97% to $60.7 million in 2022, then crashed by 51.81% to $29.2 million in 2023, then dropped by 7.47% to $27.1 million in 2024, then plummeted by 31.12% to $18.6 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Non-Current Assets are $18.6 million (Q4 2025), $27.1 million (Q4 2024), and $29.2 million (Q4 2023).